SUDA Pharmaceuticals Ltd. has appointed Dr. Reuben Benjamin to its Scientific Advisory Board for the iNKT cell therapy platform. Benjamin is an internationally recognised expert in the field of cellular immunotherapies for the treatment of blood cancer. At King's College London, UK, Dr. Benjamin leads the plasma cell disorder service and CAR-T cell programme. He is also a Consultant Haematologist and Honorary Senior Lecturer with an interest in multiple myeloma, stem cell transplantation and cell therapy. Benjamin was the Chief Investigator of the CALM clinical trial.